The maiden human trial of a potential tuberculosis drug — the first in six years — has now commenced.
Known as TBA-354, the promising drug comes from a class of chemicals known to be effective against drug-sensitive and drug-resistant tuberculosis, deemed a major public health concern because it can derail progress made in TB treatment and care. The proportion of drug-resistant TB of the global TB numbers has stayed at the same level in recent years, but new cases rise by almost half a million annually, according to the World Health Organization.
Although considered a milestone, this news also hints at the sad state of research and development for TB drugs.